tiprankstipranks
Advertisement
Advertisement

CTNM Stock Latest News

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
RatingsBuy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
2d ago
CTNM
Contineum initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Contineum initiated with an Outperform at LifeSci Capital
2d ago
CTNM
Contineum reports Q2 EPS (40c), consensus (45c)
PremiumThe Fly
Contineum reports Q2 EPS (40c), consensus (45c)
3d ago
CTNM
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
PremiumRatings
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
3d ago
CTNM
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership
PremiumCompany Announcements
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership
20d ago
8K
CTNM
Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry
PremiumThe FlyContineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry
1M ago
CTNM
Contineum Stockholders Hold 2026 Virtual Annual Meeting
Premium
Company Announcements
Contineum Stockholders Hold 2026 Virtual Annual Meeting
1M ago
8K
CTNM
Contineum price target raised to $16 from $14 at Morgan Stanley
Premium
The Fly
Contineum price target raised to $16 from $14 at Morgan Stanley
3M ago
CTNM
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
PremiumCompany Announcements
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
3M ago
8K
CTNM
Contineum reports positive topline data from exploratory PIPE-791 Phase 1b
PremiumThe Fly
Contineum reports positive topline data from exploratory PIPE-791 Phase 1b
3M ago
CTNM
Contineum price target raised to $20 from $14 at Baird
PremiumThe Fly
Contineum price target raised to $20 from $14 at Baird
5M ago
CTNM
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress
PremiumCompany Announcements
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress
5M ago
8K
CTNM
Contineum reports Q4 EPS (49c), consensus (39c)
PremiumThe FlyContineum reports Q4 EPS (49c), consensus (39c)
5M ago
CTNM
Is CTNM a Buy, Before Earnings?
Premium
Pre-Earnings
Is CTNM a Buy, Before Earnings?
5M ago
CTNM
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
Premium
Company Announcements
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
6M ago
8K
CTNM
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe Fly
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
7M ago
CTNM
Contineum 7.4M share Spot Secondary priced at $12.25
PremiumThe Fly
Contineum 7.4M share Spot Secondary priced at $12.25
8M ago
CTNM
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
PremiumCompany Announcements
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791
8M ago
8K
CTNM
Contineum offers to sell $75M in common stock
PremiumThe Fly
Contineum offers to sell $75M in common stock
8M ago
CTNM
Contineum price target lowered to $14 from $16 at Baird
PremiumThe FlyContineum price target lowered to $14 from $16 at Baird
8M ago
CTNM
Contineum price target lowered to $22 from $25 at RBC Capital
Premium
The Fly
Contineum price target lowered to $22 from $25 at RBC Capital
8M ago
CTNM
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
Premium
Ratings
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
8M ago
CTNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >